Psilocybin has been gaining a great deal of interest in recent days for a variety of reasons, and as more scholars and researchers from different disciplines around the world have started to recognize its potential the number of clinical uses for it is also increasing.
On Monday, Shortwave Pharma Inc. announced that it had signed a clinical trial agreement with the Sheba Fund for Health Services and Research and the two head Investigators’ at the Sheba Medical Centre Department for Eating Disorders.
The new agreement will appoint Shortwave as the exclusive commercial partner in an “investigator-initiated, open-label, phase II study of the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa.”
Photo via Shortwave Pharma
Read more: Lobe Sciences partners with iNGENū for new clinical trials in Australia
Read more: Serenus Global becomes Health Canada licensed psilocybin distributor
Shortwave Pharma is an Israeli pre-clinical stage biotech company focused on the development of novel formulations of psilocybin, other active pharmaceutical ingredients (APIs) and custom-designed delivery methods for those drugs. Treating mental and physical health disorders is the company’s primary objective.
The Centre for Eating Disorders at the Sheba Medical Centre is the largest facility of its kind in Israel. The centre provides treatment for adult patients suffering from a variety of eating disorders including anorexia nervosa, binge eating disorder and bulimia nervosa. The facility employs physicians, social workers, dietitians and psychologists.
Shortwave says that the new trial will be the first of its kind in Israel. It also says that the organizations’ have received approval from the Israeli Ministry of Health for the new research endeavour and are currently preparing to recruit participants.
The patent-pending psilocybin-based formulation created by Shortwave is intended to target several receptors that contribute to the prevalence of anorexia via a proprietary oral (or buccal) method of administration.
Both Shortwave and the Sheba Fund have agreed to cooperate going forward post-trial and to consider an ensuing study utilizing Shortwave’s psilocybin-based formulation and oral delivery method.
